GLP-1 medications have completely changed the way many patients and clinicians think about weight and metabolic health. Agents like semaglutide and tirzepatide have moved from specialist conversations into everyday primary care, fueled by striking clinical trial results and constant media coverage.
The clinical evidence is real. Trial data for these agents show meaningful reductions in cardiovascular events, not just weight. For patients with obesity and established cardiovascular disease, the case for treatment is strong. For patients without cardiovascular disease, the decision is more individualized—and more complex.
What has changed most visibly is patient demand. Patients are arriving at appointments asking about these medications by name. Some have already tried them through telehealth platforms or compounding pharmacies. Clinicians are managing expectations, adjusting doses, and in some cases dealing with side effects from unmonitored use.
The prescribing conversation now requires more nuance. Not every patient who asks is a good candidate. Contraindications exist. Insurance coverage is inconsistent, and the drugs are expensive without coverage. Compounded versions, while accessible, lack the safety data of the approved formulations. These are real points that need to be part of the discussion.
The broader shift is toward treating obesity as a chronic disease with metabolic consequences—not a lifestyle choice or a willpower problem. This framing helps patients engage with treatment more honestly and helps clinicians approach management with appropriate long-term expectations.
GLP-1s are part of that management, not a cure. Discontinuation typically leads to weight regain. The conversation about long-term use, monitoring, and realistic goals is as important as the initial prescribing decision.
